|
|
|
| Effects of Intravitreal Injection of Ranibizumab or Conbercept Combined with AGV on Neovascular Glaucoma and Their Influence on VEGF and IL-6 Levels in Aqueous Humor |
| WANG Qian, ZHAO Xiaoxia, WU Juan, et al |
| Xining First People's Hospital, Qinghai Xining 810000, China |
|
|
|
|
Abstract Objective: To explore the effects of intravitreal injection of ranibizumab or conbercept combined with ahemd glaucoma valve (AGV) in the treatment of neovascular glaucoma (NVG) and their influence on vascular endothelial growth factor (VEGF) and interleukin- 6 (IL-6) levels in aqueous humor. Methods: A total of 96 patients (96 eyes) with NVG admitted to our hospital from January 2016 to May 2018 were selected, and the clinical data of all patients were retrospectively analyzed. Patients were divided into ranibizumab group (group A, 34 cases, 34 eyes), conbercept group (group B, 33 cases, 33 eyes) and control group (group C, 29 cases, 29 eyes) according to different treatment regimens. The neovascularization regression of iris and chamber angle surface was observed among patients. The intraocular pressure, visual acuity and aqueous humor VEGF and IL-6 levels in the three groups were compared before and after surgery. The incidence rate of postoperative complications was recorded. Results: The neovascularization regression of iris and chamber angle surface was good in groups A and B, and there were still new blood vessels in group C, and the difference among the three groups was significant (P<0.05), and there was no statistical difference between group A and group B (P>0.05). There were statistical significance in the between-group effect, time-point effect and interaction of time-point and between-group of intraocular pressure among the three groups before surgery and at 2 w, 1 month, 3 months and 6 months after surgery (P<0.05). The intraocular pressure in the three groups at 2 w, 1 month, 3 months and 6 months after surgery was significantly decreased compared with that before surgery, and the improvement of visual acuity in group A and group B was better than that in group C at 6 months after surgery (P<0.05), but there were no significant differences in the above indexes between group A and group B (P>0.05). There was no significant difference in visual acuity among the three groups at 6 months after surgery (P<0.05). After treatment, the levels of VEGF and IL-6 in aqueous humor were decreased significantly in the three groups compared with those before treatment (P<0.05), and the comparisons of differences of the above indexes in the three groups before and after treatment were statistically significant (P<0.05). There was no statistically significant difference in the incidence rate of complications among the three groups (P>0.05). Conclusion: Intravitreal injection of ranibizumab or conbercept combined with AGV both have reliable efficacy and safety in the treatment of NVG, and they can effectively reduce intraocular pressure, improve visual acuity, promote neovascularization regression, and inhibit the expression of vasoactive substances and inflammatory factors in aqueous humor. The two drugs have comparable treatment effects.
|
|
|
|
|
|
[1] 刘洋,陈春生,马君鑫,等.康柏西普玻璃体腔注射联合多种手术治疗新生血管性青光眼疗效观察[J].检验医学与临床,2018,15(12):1777~1779.
[2] 张少维,黄毅,李琴等.全视网膜光凝联合Ahmed引流阀植入术及雷珠单抗玻璃体腔注射治疗新生血管性青光眼[J].中国眼耳鼻喉科杂志,2017,17(1):33~35,48.
[3] 汤翠翠,邹玉平,邹秀兰,等.玻璃体腔注射雷珠单抗联合内窥镜引导睫状体光凝治疗新生血管性青光眼[J].暨南大学学报(自然科学与医学版),2018,39(1):24~29.
[4] 高琳,刘苇.雷珠单抗联合Ahmed阀植入与雷珠单抗联合小梁切除术治疗新生血管性青光眼的疗效评价比较[J].中华实验眼科杂志,2018,36(8):613~618.
[5] 郭洁,李秋明,董淑倩,等.玻璃体腔注射雷珠单抗辅助23G玻璃体切除联合Ahmed阀植入术治疗新生血管性青光眼[J].中国实用眼科杂志,2017,35(6):617~621.
[6] 刘琳琳,王辉,蒋贻平,等.联合抗VEGF药物的综合疗法治疗新生血管性青光眼的临床疗效[J].眼科新进展,2018,38(11):1066~1069.
[7] 林志辉,王志亮,王伟,等.玻璃体内注射雷珠单抗联合氩激光治疗缺血性新生血管性青光眼的临床观察[J].中国药房,2018,29(10):1380~1383.
[8] 张爱平.玻璃体腔注射康柏西普联合小梁切除术及视网膜光凝治疗新生血管性青光眼[J].山西医药杂志,2018,47(15):1753~1755. |
|
|
|
2021, Vol. 27 
